VIVOSIM LABS INC (VIVS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.28-0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VIVS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | FY 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | 1.5 | 0.0 | 2.2 | 3.1 | 4.6 | 4.2 | 1.5 | 0.6 | 0.4 | 1.2 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 4.6 | 4.2 | 1.5 | 0.6 | 0.4 | 1.2 |
| Cost of Revenues | — | — | 0.0 | — | — | — | 0.0 | 0.3 | 0.5 | 1.0 | 1.0 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | 7.1 | 7.4 | 7.7 | 9.7 | 9.2 | 9.7 | 15.7 | 18.1 | 15.1 | 20.9 | 22.3 | 22.1 | 17.9 | 13.1 | 7.1 |
| R&D Expenses | 4.3 | 4.2 | 5.0 | 5.5 | 8.9 | 3.3 | 1.1 | 5.3 | 14.8 | 18.0 | 19.5 | 18.0 | 12.9 | 8.0 | 3.4 |
| Operating Income | (11.3) | (11.5) | (12.6) | (15.1) | (17.7) | (11.5) | (16.8) | (21.5) | (27.3) | (35.3) | (38.6) | (38.6) | (30.3) | (20.6) | (9.3) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | 0.0 | 0.0 | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 |
| Interest & Investment Income | 0.2 | 0.3 | 0.1 | 0.4 | 0.5 | 0.0 | 0.0 | 0.6 | 0.7 | 0.5 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | (0.2) | (0.1) | (0.0) | (0.0) | 1.1 |
| Other Non-Operating Income / Expenses | (1.0) | (2.4) | 10.1 | 0.4 | 0.5 | 0.0 | 0.0 | 2.8 | 0.6 | 0.5 | 0.2 | 0.1 | 0.2 | (5.2) | (34.2) |
| EBT, Incl. Unusual Items | — | (13.8) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | |||||||||||||||
| Net Income | (12.3) | (13.8) | (2.5) | (14.7) | (17.3) | (11.4) | (16.8) | (18.7) | (26.6) | (34.8) | (38.4) | (38.6) | (30.1) | (25.8) | (43.6) |
| Per Share | |||||||||||||||
| Basic EPS | (2.35) | (5.35) | (1.70) | (1.60) | (1.98) | (1.32) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (2.35) | (5.35) | (1.70) | (1.60) | (1.98) | (1.32) | — | — | — | — | — | — | — | — | 0.00 |
| Revenue per Share | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 5.2 | 2.6 | 1.5 | 9.1 | 8.7 | 8.7 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 5.2 | 2.6 | 1.5 | 9.1 | 8.7 | 8.7 | — | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | (11.3) | (12.4) | (14.8) | (17.4) | (11.3) | (16.8) | (20.3) | (26.3) | (34.0) | (37.4) | (37.8) | (29.8) | (20.3) | (9.1) |
| EBIT | (11.3) | (11.5) | (12.6) | (15.1) | (17.7) | (11.5) | (16.8) | (21.5) | (27.3) | (35.3) | (38.6) | (38.6) | (30.3) | (20.6) | (9.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.